Draper Associates Leads HexemBio's $10.4M Seed to Rejuvenate Aging Blood Stem Cells
[ ← Newsroom ]
Future Tech · April 7, 2026 · Draper Associates · 00 Min

Future Tech

Your blood stem cells are the source of your entire immune system. As they age, your body's defenses weaken. We led HexemBio's $10.4 million seed round because the company found a way to make old blood stem cells young again, without gene editing.

Rejuvenation outside the body

HexemBio uses a proprietary synthetic niche, an engineered environment that mimics the conditions where stem cells are born, to rejuvenate a patient's own blood stem cells outside the body. The renewed cells are then returned through a standard IV infusion. The first clinical target is blood cancer, where rebuilding a healthy immune system can be the difference between recovery and relapse.

The company emerged from stealth with our round. It was founded by CEO Gabriel Levesque Tremblay alongside CTO Samira Kiani and CBO Samet Yildirim. We led the seed, joined by SOSV, Seraphim Space, and Treeo VC.

Why we led the round

We fund the future first, and few futures are bigger than changing how we age, extending healthy human lifespan. The premise is simple: the decline of blood stem cells is a major driver of aging itself. Start with the bone marrow transplant patients who need it most, prove the science in the clinic, and the long-term implications reach far beyond any single disease. That is precisely the kind of audacious, well-grounded bet we look for, and we are proud to lead it.

On this page

Companies in this story

More from newsroom